Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.
#40 most reported symptom for this vaccine
Swelling has been reported 165 times in association with RSV (Arexvy) vaccination in VAERS. This represents 1.8% of all 9,330 reports for this vaccine.
Among these reports, 0 mentioned death (0.00%) and 5 involved hospitalization (3.0%).
Swelling is the #40 most frequently reported symptom for RSV (Arexvy) out of 947 total symptoms.
Disclaimer: VAERS reports describe events that occurred after vaccination but do not establish that the vaccine caused the event. Many reported symptoms may be coincidental or related to underlying conditions.
Seeing 165 reports of Swelling after RSV (Arexvy) vaccination may seem alarming, but context is critical.
The mortality rate among these reports is very low at 0.00%, suggesting most cases are non-fatal.
This data comes from the Vaccine Adverse Event Reporting System (VAERS), jointly managed by CDC and FDA.